

*Ministry of Defence*

## **Synopsis of Causation**

### **Cancer of the Kidney**

Author: Dr Doug Dingwall, Medical Author, Medical Text, Edinburgh  
Validator: Professor Jonathan Waxman, Imperial College, London

September 2008

## **Disclaimer**

---

This synopsis has been completed by medical practitioners. It is based on a literature search at the standard of a textbook of medicine and generalist review articles. It is not intended to be a meta-analysis of the literature on the condition specified.

Every effort has been taken to ensure that the information contained in the synopsis is accurate and consistent with current knowledge and practice and to do this the synopsis has been subject to an external validation process by consultants in a relevant specialty nominated by the Royal Society of Medicine.

The Ministry of Defence accepts full responsibility for the contents of this synopsis, and for any claims for loss, damage or injury arising from the use of this synopsis by the Ministry of Defence.

# 1. Definition

---

1.1. “**Cancer of the kidney**” is a broad term which covers several malignant [neoplasms](#) involving [renal](#) tissues:

- renal cell carcinoma (RCC); (*hypernephroma* is a synonymous term although it is no longer favoured by all)
- transitional cell carcinoma
- renal sarcoma
- renal medullary carcinoma
- collecting duct tumour
- renal lymphoma and renal leukaemic infiltration
- [metastatic](#) tumour of the kidney
- Wilm’s Tumour (nephroblastoma)
- oncocytoma

1.2. **RCC** accounts for about 85% of all [primary](#) renal cancers.

1.2.1. It arises in the renal [tubule epithelium](#) and accounts for about 3% of all adult malignancies.

1.2.2. In Western populations there are approximately 8 new cases per 100,000 per year, in the ratio male:female of approximately 3:2.

1.2.3. It is diagnosed mainly in adults in their fifties, sixties or seventies and is familial in about 4% of cases.

1.2.4. It is rare in children and adolescents.<sup>1,2</sup>

1.2.5. **Classification** In the past, RCC has been classified by cell type, (employing labels such as clear, granular, spindle, and oncocytic) or by pattern of growth (employing labels such as acinar, papillary, and sarcomatoid). More recently, however, classification takes into account several sets of defining factors : [histochemistry](#), [morphology](#) and [cytogenetic](#) characteristics. Five types have been defined in this way:

- clear cell
- chromophilic (papillary)
- chromophobic
- oncocytic

- collecting duct (Bellini duct)
- 1.2.5.1. The **clear cell** type accounts for over 75% of RCCs and typically has a specific [chromosome](#) abnormality (3p).
  - 1.2.5.2. The **chromophilic (papillary)** type accounts for about 15% of RCCs, may be multifocal and bilateral, is often small and typically may have multiple chromosome abnormalities (including 7, 17, 16 and Y but not 3p).<sup>3,4</sup>
  - 1.2.5.3. The **chromophobic** type accounts for about 4% of RCCs is usually well [circumscribed](#) and has a reduced chromosome number but no 3p abnormality.<sup>5,6,7</sup>
  - 1.2.5.4. The **oncocytic** type has been thought to account for about 3% of RCCs. It can grow to be quite large and has distinct histological characteristics but no consistent chromosomal abnormalities. However, distinction between an oncocytic RCC and an oncocytoma (benign) can be difficult, thus casting doubt on the reliability of diagnosis of malignancy within this subgroup. Indeed some regard it as distinct from RCC altogether.
  - 1.2.5.5. The **collecting duct (Bellini duct)** type is rare, arises from [medullary](#) or [pelvic](#) tissue, and has a distinctive [histological](#) appearance<sup>8</sup> but no consistent chromosomal abnormalities. It can be a very invasive tumour. There is still some uncertainty about whether all renal medullary carcinomas and collecting duct carcinomas should be considered as RCC subtypes or whether some may be separate entities.<sup>9,10,11,12</sup>
- 1.3. **Transitional cell carcinoma** is the next most common at around 8%, but it arises in the renal pelvis so is not considered further here.
  - 1.4. **Renal sarcoma** accounts for 1% to 2% of primary renal cancers.
    - 1.4.1. The most common is **fibrosarcoma** which is a very aggressive tumour.
    - 1.4.2. Rarer are leiomyosarcoma, liposarcoma, rhabdomyosarcoma, osteogenic sarcoma, carcinosarcoma, malignant fibrous histiocytoma, angiosarcoma and malignant hemangiopericytoma. All are very aggressive tumours.
  - 1.5. **Renal medullary carcinoma**, considered by some to be distinct from RCC, is a rare tumour affecting patients with [sickle cell trait or disease](#)<sup>9,10,13</sup>. It is a very aggressive tumour.
  - 1.6. **Collecting duct tumour** may sometimes be distinct from RCC.<sup>14,8,12,11</sup> It is a rare but very aggressive tumour.
  - 1.7. **Renal lymphoma** and **renal leukaemic infiltration** occur in about one third of patients dying from the [systemic](#) disease and disseminate mainly via the blood stream. Primary renal lymphoma is rare.
  - 1.8. **Metastatic tumour involving the kidney** is more common than primary renal cancer and occurs in over 10% of people dying from all cancers. The usual primary sources are:
    - lung

- breast
- stomach
- bowel
- [malignant melanoma](#).

1.9. **Wilm's Tumour** is the commonest renal cancer in children.

1.9.1. It occurs in about 8 of a million children under the age of 15, being commonest between 2 and 5 years.

1.9.2. Rarely, RCC can occur in children too,<sup>15,1</sup> as can other rare tumours, including rhabdoid tumour of the kidney, mesoblastic nephroma, and multilocular cystic nephroma.<sup>16</sup>

1.9.3. Rarely, Wilm's tumour can occur in adults.<sup>17,18</sup>

1.9.4. Two forms of Wilm's tumour can be identified histologically:

- **favourable** which is the most usual and has cell characteristics that do not include [anaplasia](#)
- **unfavourable** which has cell features including markedly enlarged and [hyperchromatic nuclei](#) and is more likely in older patients. One subtype of this form is **clear cell sarcoma**.

1.10. **Oncocytoma** is thought to be a benign tumour and is managed by nephrectomy. Recurrence and metastasis are extremely rare, so it is not considered further here.

## 2. Clinical features

---

**Clinical Features** vary with the tumour type.

2.1. **RCC** classically presents with a triad of symptoms:

- [haematuria](#) (frank or microscopic)
- loin pain
- swelling in the abdomen or loin

2.1.1. However, this triad occurs in only 10% of cases and symptomless renal cancer is more often found incidentally, during other investigative procedures such as [computed tomography](#) (CT) or [magnetic resonance imaging](#) (MRI).

2.1.2. Cases can present with sudden onset of [scrotal varicocele](#) due to venous obstruction within the abdomen, but this is very unusual.

2.1.3. Unfortunately, presentation can often be due to symptoms caused by metastases:

- [pathological fractures](#)
- cough
- [haemoptysis](#)
- [dyspnoea](#) related to [pleural effusions](#)
- [lymph node](#) enlargement

2.1.4. An RCC may secrete substances known as para-neoplastic factors that cause generalised symptoms such as weakness, weight loss, anaemia, fever, night sweats and [malaise](#).

2.1.5. As the kidney is a major source of hormones involved in many [homeostatic mechanisms](#), RCC can stimulate abnormal hormone production which can cause a variety of **para-neoplastic syndromes**. Features include:

- [hypertension](#)
- [hyperglycemia](#)
- [hypercalcaemia](#)
- [polycythaemia](#)
- [eosinophilia](#)
- clotting disorders

- leukaemia-like reactions
- [hepatic](#) dysfunction (Stauffer's syndrome)
- [Cushing's syndrome](#)
- feminisation or masculinisation
- [galactorrhea](#)
- [neuromyopathy](#)
- [amyloidosis](#).

RCC, in summary, can present with a wide variety of clinical features, some very non-specific.

2.2. **Renal Sarcoma** can have a very similar presentation to RCC and may be very difficult to distinguish clinically from an RCC that shows [sarcomatoid](#) change. However, factors which can be useful include:

- position of origin within the kidney
- large size with no lymph node involvement
- occurrence of fat or bone tissue, suggestive of liposarcoma or osteosarcoma
- [hypovascular](#) pattern on [angiography](#)
- tendency to displace rather than invade the surrounding tissues

2.2.1. Leiomyosarcoma is particularly liable to grow very rapidly and metastasises readily.

2.2.2. Osteogenic sarcoma is often very hard due to extensive [calcification](#).

2.3. **Renal medullary carcinoma** presents with haematuria, flank pain and a renal mass. It has often invaded local tissues and metastasised by the time of diagnosis.

2.4. **Collecting duct tumour** displays features<sup>19</sup> that are very similar to those of renal medullary carcinoma.

2.5. **Renal lymphoma** and **renal leukaemic infiltration** usually occur late in the development of the systemic disease and may contribute comparatively little to the patient's clinical state, although, exceptionally, renal failure can occur.

2.6. **Metastatic tumour of the kidney** is usually multifocal and almost always associated with metastatic lesions at other sites.

2.7. **Wilm's Tumour** usually occurs in one kidney but can occasionally be [bilateral](#). It most commonly presents as an abdominal mass, which may be symptomless.

2.7.1. However, it may cause pain and/or vomiting and haematuria may occasionally be

detected on examination.

2.7.2. It may also present with raised blood pressure.

2.7.3. It can occur in association with [congenital](#) abnormalities, usually of [genitourinary](#) type.

2.7.4. It tends to present later in adults than in children.<sup>18</sup>

**Staging systems**, which are applied at the time of initial diagnosis, aid choice of therapy and assessment of prognosis. They vary slightly with tumour type.

2.8. In **RCC** a number of staging systems have been described.

2.8.1. The **Robson system** was formerly employed, allocating cases to Stages I – IV.

2.8.2. Since the late 1990's the **TNM** (tumour, node, metastasis) system has been found preferable. In this system:

- local spread into surrounding tissues is allocated a T grade
- degree of metastasis into local lymph nodes is allocated an N grade
- presence or otherwise of detectable distant metastases is allocated an M grade

2.8.3. Alternative staging systems are employed by some, combining TNM with other grading methods.

2.9. In **Renal sarcoma**, TNM staging is employed for tumours in children.<sup>20</sup>

2.9.1. In adults a variant that includes tumour size may be employed.<sup>21,22</sup>

2.10. **Renal medullary carcinoma** and **collecting duct tumour** can be staged using the TNM method.<sup>19</sup>

2.11. In **renal lymphoma**, **renal leukaemic infiltration** and **metastatic tumour of the kidney** staging will be applied to the primary disease.

2.12. In **Wilm's Tumour** a 5 stage method based on clinical findings at diagnosis and at initial operation is usually employed in children and adults:

- Stage I - the tumour is confined to the kidney and is completely excised with the tumour capsule intact
- Stage II - the tumour is confined to the kidney but the capsule is penetrated or tumour is present in the [peri-renal](#) soft tissue
- Stage III - the tumour has inoperable local spread left after surgery. This is confined to the abdomen and may involve local lymph nodes
- Stage IV - the tumour is characterised by distant metastases, generally involving the lungs and occasionally the liver



- Stage V - the tumour occurs in both kidneys at the time of diagnosis

### 3. Aetiology

---

- 3.1. Some insight into the possible **mechanisms of renal carcinogenesis** can be gleaned from studies of von Hippel-Lindau (VHL) disease.
  - 3.1.1. This is a rare familial disorder in which patients develop RCC and other tumours. It is typified by the **mutation** of a **germline gene** known as the **VHL gene**.<sup>23,24</sup>
  - 3.1.2. When normal tissues are deprived of oxygen for any reason, complex mechanisms stimulate cells into **adaptive responses** including new blood vessel formation and **anaerobic** mobilisation of cell energy sources.<sup>25,26</sup> In healthy tissues this adaptive process is kept inactive by a series of gene-mediated factors<sup>27,28</sup> in which the **normal VHL gene** features.<sup>23</sup>
  - 3.1.3. In VHL disease, however, the **mutated VHL gene** fails to function properly and the adaptive process is not held in check. Tissues which have a good oxygen supply may be stimulated inappropriately, perhaps encouraging malignant growth.<sup>29,30</sup>
- 3.2. **Assessment of risk** can be studied by comparing the occurrence of disease in large groups exposed to the risk factor in question with unexposed control groups.
- 3.3. In considering the results of studies on risk factors, **individual susceptibility** has to be taken into account.
  - 3.3.1. In one study the risk of developing RCC after exposure to an environmental risk factor was different in two groups defined by the presence of two different **alleles** of the same gene.<sup>31</sup> One group was more susceptible than the other to the risk factor being studied.
  - 3.3.2. Susceptibility of an individual to development of cancer is likely to involve the genetic pattern that defines that individual, and this may change as the individual ages.
- 3.4. The possibility of **viruses** being involved in human renal carcinogenesis has featured little in recent research and is thought to be unlikely as there is no apparent increase in incidence of renal cancers in groups most vulnerable to virus infections nor is there any suggestion of **horizontal transmission** in humans.

#### RCC risk factors

##### 3.5. Inherited diseases

- 3.5.1. The commonest, but still relatively rare, is **von Hippel-Lindau disease** (described above) which is a multisystem familial cancer syndrome occurring in approximately 1 in 36,000 of the population. Development of clear cell RCC in later life is a common feature of this syndrome, typified by mutation of the germline VHL gene.<sup>23,32,33</sup>
- 3.5.2. Another uncommon **autosomal dominant** disorder is **tuberous sclerosis complex** which is characterised by mental retardation, seizures and benign tumours of the heart, lung, skin, central nervous system and kidney. Sometimes malignancy can develop, especially in the kidney, the commonest being RCC. Non-VHL gene mutations have been described.<sup>34,35,36</sup>

3.5.3. RCC has been thought by some to have links with the rare **autosomal dominant polycystic kidney disease** but these have **not** been convincingly demonstrated.<sup>37,38</sup>

3.5.4. **Hereditary papillary cell renal carcinoma** is a rare inherited RCC thought to be genetically distinct from other inherited renal cancers.<sup>39,40</sup>

3.5.5. Virtually all patients with the **clear cell** variant of RCC have a mutated VHL gene.

### 3.6. Genetic factors

3.6.1. People with a **family history** of cancer of the kidney in a first or second degree relative have been found to have a slightly increased risk of RCC.<sup>41,42</sup>

3.6.2. A family history of other cancers does not seem to be associated with RCC risk.<sup>41</sup>

3.6.3. A family history of cancer of the kidney does not seem to be associated with any additional increase in susceptibility to external risk factors.<sup>41</sup>

### 3.7. Chronic renal disease

3.7.1. Studies have shown that the risk of RCC is very much much higher in patients who suffer from chronic renal failure, with or without acquired cystic kidney disease,<sup>43,44</sup> estimates varying from 20 to 100 times more.<sup>45,46,47,48</sup>

### 3.8. Other risk factors

3.8.1. A number of studies have been carried out to determine if certain other factors are associated with an increased risk of RCC. Most of these studies involve analysis of the occurrence of the risk factors in groups of RCC patients compared with the occurrence in other patient groups where RCC has not been diagnosed.

3.8.2. As RCC has a very low prevalence in the population, such studies are inevitably limited in the number of cases available for comparison with controls, particularly after the study groups are subdivided to account for several potentially [confounding](#) factors.

3.8.3. Most of the studies express results in the form of [relative risk](#) (RR) or the very similar [odds ratio](#) (OR). An RR of 2.0, for example, indicates that the associated risk is doubled while an RR of 0.5 indicates that the risk is halved. Very few of the studies produce an RR above 2.0 and the fairly wide [confidence interval](#) (CI) quoted in most of the studies limits the significance of the findings. This translates into at most only very slight association between the factor under study and the occurrence of RCC.

3.8.4. No standard definition of “prolonged exposure” is consistently used throughout the studies, but a period of over 10 years is regarded as prolonged in some.

3.8.5. Some of the studies reveal at most only very slight associated risk from **constitutional factors** which include:

- obesity<sup>41,42,49,50,51,52</sup>
- hypertension<sup>53,54,55</sup>

- [oestrogenic hormones](#) <sup>56,57,58</sup>

3.8.6. Others reveal at most only very slight associated risk from prolonged exposure to **external factors** which include:

- tobacco smoking <sup>42,50,59,60,61,62,63,64,65</sup>
- industrial solvents including trichloroethylene <sup>66,67,68,69,70,71,72</sup>
- cadmium <sup>68,73</sup>
- lead <sup>68</sup>
- solder fumes <sup>68</sup>
- asbestos <sup>66</sup>
- copper sulphate <sup>69</sup>
- pesticides <sup>31,69</sup>
- paints <sup>68</sup>
- mineral oils <sup>68</sup>
- cutting fluids <sup>68</sup>
- benzene <sup>68</sup>
- polycyclic aromatic hydrocarbons <sup>68</sup>

3.8.7. Others reveal at most only very slight associated risk from prolonged **work in certain industries** which include those involving:

- dry cleaning <sup>66</sup>
- soldering <sup>68</sup>
- welding <sup>68</sup>
- milling <sup>68</sup>
- petrol station attending <sup>74</sup>

3.8.8. Others reveal at most only very slight associated risk from prolonged use of certain **therapeutic drugs** which include:

- paracetamol <sup>75,76,77</sup>
- aspirin <sup>76,77</sup>

- phenacitin <sup>76,77</sup>
- non-steroidal anti-inflammatory agents <sup>77</sup>
- amphetamine <sup>55,56</sup>

3.8.9. Others reveal at most only very slight associated risk from **regular dietary factors** which include:

- high energy diet <sup>51</sup>
- fried meats <sup>51,78</sup>
- low intake of vitamin E <sup>51</sup>
- low intake of magnesium <sup>51</sup>

3.8.10. There may well be additional factors that have not yet been researched.

3.8.11. The “other” risk factors listed above are associated with at most only very slight increase in RCC. But RCC occurs in an average of only 8 per 100,000 of the population per year in the western world, so the risk to an average individual is very small indeed and the risk to an individual exposed to any of these “other” factors only slightly greater.

3.8.12. Also, since these “other” risk factors involve constitution, habits, diet, drugs and work exposures, excluding the confounding effect of some of these factors on others under consideration is extremely difficult, even when studying large groups, and virtually impossible when considering the causes in an individual case.

3.8.13. Furthermore, in each group exposed to a risk factor under study there will be individuals of widely varying susceptibility to that factor. Assessing the risk associated with that factor in an individual is thus extremely difficult, as precise measures of individual susceptibility are not yet available.

3.8.14. These “other” risk factors, therefore, while contributing to research on mechanisms of renal carcinogenesis and to definition of health policy for populations, are of very little value in defining causes of RCC in individuals.

### 3.9. Exposure to radioactivity

3.9.1. After the Chernobyl accident in 1986, the rate of RCC occurrence per 100,000 people living in the contaminated area gradually increased from 4.7 in 1986 to 7.5 in 1998. Caesium 137, which is excreted mainly through the kidneys, was the main contaminant. <sup>79,80</sup> However there are doubts about the reliability of the locally collected data and the significance of the findings is thus very limited.

3.9.2. In 1988, a cohort of over 22 thousand men who participated in the United Kingdom's atmospheric nuclear weapon tests and experimental programmes in Australia and the Pacific Ocean between 1952 and 1967 was studied and compared with a matched control cohort of servicemen. <sup>81</sup> The study focussed on mortality from various causes, and on mortality and incidence for 27 types of cancer. No evidence was found of increased incidence of solid tumours in the test group compared with the controls. Further follow

up analyses of the cohorts, published in 1993<sup>82</sup> and 2004,<sup>83</sup> produced the same conclusion.

3.9.3. A few cases of RCC occurring 25 to 30 years after radiotherapy in the 1950's and 1960's have been reported.<sup>84,85</sup> In all cases the therapy was for other malignancies therefore the significance of any link between the radiotherapy itself and the later RCCs is unclear. Another factor to be considered is that radiotherapy doses were much higher then than now.

### 3.10. **Trauma**

3.10.1. There is no clear association between renal cancer with trauma except in one large international [case-control study](#) of renal-cell cancer<sup>86</sup> where the authors concluded that the link they found was very unlikely to be significant because of unreliability of recall.

### **Other renal tumour risk factors**

3.11. No studies of risk factors for **renal sarcoma** have been reported.

3.12. Studies of **renal medullary carcinoma** have found various characteristics suggesting they form a distinct group with gene patterns different from those in RCC and that tissue hypoxia associated with **sickle cell trait** may be involved in tumour development.<sup>87,88</sup>

3.13. Genetic changes have been found in **collecting duct tumour**<sup>89</sup> but their significance is not fully established.

3.14. The causes of **renal lymphoma, renal leukaemic infiltration and metastatic tumour of the kidney** are those of the primary disease.

3.15. **Wilm's tumour** in children is associated with several **genetic abnormalities** and with several **congenital abnormality syndromes**. However, a family history of the tumour is very uncommon.

3.15.1. One study found that Wilm's tumour occurred twice as often in the children of mothers who had a heavy **smoking** habit than in those of non-smokers.<sup>90</sup> However, this was not confirmed in a subsequent study of habits of parents of 200 children with a history of Wilm's tumour.<sup>91</sup>

3.15.2. A recent study describes gene abnormality in a case of **adult** Wilm's tumour.<sup>17</sup>

3.15.3. Another study demonstrated a very weak association of Wilm's tumour with **high birth weight** but **no association** with **high parental age** at birth, consumption of **coffee and tea during pregnancy**, or maternal exposure to **pesticides**.<sup>92</sup>

## 4. Prognosis

---

4.1. Prognosis in cancer of the kidney varies with the type of tumour.

4.1.1. In **RCC** several factors have a bearing on prognosis.

4.1.2. The most important prognostic factor is the strong [correlation](#) between **Robson** or **TNM staging**, applied at initial diagnosis, and 5-year survival rates.<sup>93,94,95,96</sup> With both, typical 5-year survival rates are:

- 70 – 95% where tumour is confined to the kidney; the smaller the tumour the better the prognosis
- 50 – 60% where tumour extends no further than the peri-renal fascia
- 40 – 50% where there is true venous invasion
- 25 – 30% where tumour is confined to the kidney and there is only a single metastasis in one [regional node](#)
- 15 – 20% where tumour extends no further than the peri-renal fascia and there is only a single metastasis in one regional node
- 10% where there is tumour extension beyond the peri-renal fascia or there are metastases in more than one regional node
- < 5% where there are distant metastases

4.1.3. Other factors which contribute to assessment of prognosis are:

- **Fuhrman grading**, a very useful classification which allocates microscopic changes within the nuclei of tumour cells to one of four grades.<sup>93,96,97,98</sup> Some now feel that redefinition of this system to include only two grades would be preferable.
- variations in tumour **cell subtype**
- **sarcomatoid** growth pattern changes<sup>99,100,101</sup> and **collecting duct** cell type both have a particularly poor prognosis
- **chromophilic** and **chromophobic** types have been thought to have a better prognosis than clear cell type<sup>102</sup> but they can be less responsive to some therapies and may have a worse prognosis in advanced cases.

4.1.4. In **RCC in the earlier stages**, [nephrectomy, radical](#) or partial, is the usual treatment of choice and 5-year survival rates of over 60% are common.

4.1.4.1. Post-surgery radiotherapy offers no benefit and is not indicated.

4.1.5. In **RCC in the later stages**, factors that influence survival<sup>103</sup> include:

- site and number of metastases
- the patient's general state
- fever
- [anorexia](#)
- weight loss
- malaise
- substantially raised [ESR](#)
- anaemia
- hypercalcaemia <sup>104</sup>
- [hypoalbuminaemia](#) <sup>103</sup>
- liver dysfunction
- presence of [chronic renal failure](#)

4.1.6. Treatment in the later stages seldom includes chemotherapy or hormone therapy as both are usually ineffective. However, metastases can sometimes be excised with resulting improvement in 5-year survival rates.

4.1.7. Much more promising is [immunotherapy](#) with interferon or interleukin 2, sometimes together, or combined with other drugs.

4.1.8. With ever-increasing understanding of [molecular](#) processes underlying the condition, therapies aimed specifically at these processes are being explored.

4.1.9. However, overall, later stage prognosis remains poor.

4.2. **Renal sarcoma** generally has a poor prognosis unless it is diagnosed at an early stage. <sup>105,106,107</sup>

4.3. **Renal medullary carcinoma** and **collecting duct tumour** generally have a very poor prognosis. However, significant response to therapy has been described recently. <sup>108</sup>

4.4. The presence of **renal lymphoma**, **renal leukaemic infiltration** and **metastatic tumour of the kidney** indicates distant spread from the primary source, implying a poor prognosis, but more specific assessment will depend on the overall prognosis of the primary disease.

4.5. In **Wilm's tumour** the main prognostic factors at diagnosis are size, stage and histological type (favourable or unfavourable).

4.5.1. With chemotherapy or radiotherapy after surgery, 4 year survival rates in **children** can be:



- over 90% for stages I and II with favourable histology
- 80 to 90% for stages III and IV with favourable histology
- well over 80% for stage I with unfavourable histology
- 50 to 60% for stages II to IV with unfavourable histology
- 60 to 85% for stage V (bilateral)#even with inoperable tumours, over 50% can be achieved

4.5.2. Similar figures for **adults** with Wilm's tumour have been found <sup>109</sup> although more of the adult tumours present at higher stages <sup>18</sup> and thus, overall, have a less favourable prognosis. <sup>110</sup>

## 5. Summary

---

- 5.1. Most cancers of the kidney are RCC although several other types occur.
- 5.2. They can present in many different ways and are increasingly detected at earlier stages during the course of investigations for other conditions.
- 5.3. Causes remain uncertain. Genetic, constitutional and environmental factors probably play a part in the aetiology of the condition but the exact mechanisms involved are complex.
- 5.4. Prognosis varies substantially with the type of tumour and its staging. Prognosis has improved in recent years due to earlier detection and advances in treatment. However, it remains poor for some of the tumours, especially if they are at an advanced stage at diagnosis.

## **6. Related Synopses**

---

Cancer of the Lung

Cancer of the Stomach

Cancer of the Colon

Cancer of the Rectum

## 7. Glossary

---

allele	Any one of a series of two or more different genes that occupy the same position on a chromosome.
amyloidosis	A disease process involving deposition of a glycoprotein substance between tissue cells.
anaerobic	Functioning in the absence of oxygen.
anaplasia	A cell characteristic which takes a primitive form typical of malignancy.
angiography	A X-ray technique which images blood vessels.
anorexia	Loss of appetite for food.
autosomal dominant	Requires that only one parent need have the trait (characteristic) in order to pass it to the offspring.
bilateral	Occurring on both sides.
calcification	Hardening of tissue by deposition of calcium salts.
carcinogenesis	Generation of cancer from normal cells.
case-control study	A study in which the risk factors of people with a disease are compared with those without the disease.
chromosome	The self-replicating genetic structures within cell nuclei, each chromosome having a linear array of genes.
chronic renal failure	Persistent and substantial decline in kidney function.
circumscribed	Well localised.
computed tomography	An investigation technique that uses a computer to assimilate multiple X-ray images into a two-dimensional cross-sectional image.
confidence interval	A statistical calculation which defines a range within which the true value of a variable being studied will fall with specified probability.

confounding	Distortion of the apparent effect of an exposure on risk, brought about by the association with other factors that can influence the outcome.
congenital	Pertaining to conditions present at birth.
correlation	Statistical association.
Cushing's syndrome	A disorder due to an excess of glucocorticoid hormone in the bloodstream, produced by a benign tumour of the adrenal gland.
cytogenetic	Relating to the origin and development of cells.
dyspnoea	Difficulty in breathing or laboured breathing – breathlessness.
eosinophil	A white blood cell that plays a part in allergic reactions and the body's response to parasites and fungi. Hence <i>eosinophilia</i> ; an excess of these cells above the normal.
ESR	A test which gives a non-specific index of inflammation.
galactorrhoea	The excessive, persistent or spontaneous flow of breast milk irrespective of nursing.
germline gene	A gene within cells which give rise to the reproductive cells.
gene	Unit of inheritance consisting of DNA and occupying a specific position on a chromosome.
genitourinary	Pertaining to the genital and urinary organs.
haematuria	Blood in the urine; (if easily visible it is described as <i>frank haematuria</i> ).
haemoptysis	Coughing up blood or bloodstained sputum.
hepatic	Pertaining to the liver.
histochemistry	Study of the chemical composition of tissues by means of specific staining reactions.
histological	pertaining to the study of the microscopic structure of tissues.
homeostatic mechanism	A mechanism which maintains stability in the normal body state.

horizontal transmission	Transfer of a disease from one individual to another generally within a population.
hypercalcaemia	Excessive levels of calcium compounds in the bloodstream.
hyperchromatic nuclei	Nuclei showing excessive staining. The cell nucleus holds the chromosomes.
hyperglycaemia	Excessive levels of glucose in the bloodstream.
hypertension	Increased blood pressure.
hypoalbuminaemia	An abnormally low concentration of albumin in the blood.
hypovascular	Having an abnormally low number of blood vessels.
hypoxia	Lack of oxygen.
immunotherapy	Treatment of disease by stimulating the body's own immune system.
lymph nodes	Small bean-shaped organs located along the lymphatic system throughout the body.
magnetic resonance imaging	An investigation technique used to image internal structures of the body, particularly soft tissues.
malaise	A vague feeling of being unwell.
malignant melanoma	A malignant tumour of the skin.
medullary	Relating to the inner area (of the kidney).
menarche	The start of menstrual function.
metastatic	Referring to a deposit of a malignant tumour in a distant site in the body. Hence <i>metastasis</i> , <i>metastasise</i> .
molecular	Referring to molecules, which result from two or more atoms combining by chemical bonding.
morphology	The study of the structure of an organism or cell.
mutation	A permanent change in genetic material that can be transmitted to future generations.

neoplasm	New growth, usually cancerous.
nephrectomy	Surgical removal of the kidney; (if <i>radical nephrectomy</i> , then nearby tissues and lymph nodes removed also).
neuromyopathy	A disorder of muscle due to or combined with disorder of its nerve supply.
odds ratio	A statistical calculation of the number of people with disease who were exposed to a risk factor over those with disease who were not exposed divided by the number of those without disease who were exposed over those without who were not exposed.
oestrogenic hormones	Chemical substances that produce effects that characterise female functions.
pathological fractures	Fractures occurring from minor injury due to abnormal weakness of the bone structure.
pelvic	Pertaining to the chamber between the kidney tissue and the ureter (renal pelvis), through which urine flows to the bladder.
peri-renal	Pertaining to tissues surrounding the kidney.
pleural effusion	Collection of fluid between the lung outer surface and the chest wall.
polycythaemia	An increase in the total mass of cells in the blood; primarily used to refer to an increase in the mass of red blood cells.
primary	Pertaining to the original site of a malignant tumour, from where metastases may occur.
regional node	A lymph node receiving drainage from nearby tissue.
relative risk	A statistical calculation of the proportion of of diseased people amongst those exposed to the relevant risk factor divided by the proportion of diseased people amongst those not exposed to the risk factor.
renal	Pertaining to the kidney.
sarcomatoid	Having the appearance of tumour cells that arise in tissues such as bone, cartilage, fat or muscle.

scrotal varicocele	Varicose veins in the scrotum.
sickle cell trait	A genetically determined tendency to develop sickle cell disease.
sickle cell disease	A type of anaemia developing in people with the trait.
syndrome	A set of signs or a series of events occurring together that point to a single disease or condition as the cause.
systemic	Affecting the body as a whole.
tubule epithelium	the lining tissue of the minute tubes within the kidney tissues.



## 8. References

---

- <sup>1</sup> Indolfi P, Terenziani M, Casale F et al. Renal cell carcinoma in children: a clinicopathologic study. *J Clin Oncol* 2003;21(3):530-5.
- <sup>2</sup> Huang FS, Zwerdling T, Stern LE et al. Renal cell carcinoma as a secondary malignancy after treatment of acute promyelocytic leukemia. *J Pediatr Hematol Oncol* 2001;23(9):609-11.
- <sup>3</sup> Kovacs G, Wilkens L, Papp T et al. Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis. *J Natl Cancer Inst* 1989;81(7):527-30.
- <sup>4</sup> Kovacs G, Fuzesi L, Emanuel A, Kung HF. Cytogenetics of papillary renal cell tumors. *Genes Chromosomes Cancer* 1991;3(4):249-55.
- <sup>5</sup> Kovacs A, Kovacs G. Low chromosome number in chromophobe renal cell carcinomas. *Genes Chromosomes Cancer* 1992;4(3):267-8.
- <sup>6</sup> Speicher MR, Schoell B, du Manoir S et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. *Am J Pathol* 1994;145(2):356-64.
- <sup>7</sup> Akhtar M, Kardar H, Linjawi T et al. Chromophobe cell carcinoma of the kidney. A clinicopathologic study of 21 cases. *Am J Surg Pathol* 1995;19(11):1245-56.
- <sup>8</sup> Kennedy SM, Merino MJ, Linehan WM et al. Collecting duct carcinoma of the kidney. *Hum Pathol* 1990;21(4):449-56.
- <sup>9</sup> Zdinak LA, Nik NA, Hidayat AA et al. Renal medullary carcinoma metastatic to the orbit: a clinicopathologic report. *Ophthal Plast Reconstr Surg* 2004;20(4):322-5.
- <sup>10</sup> Yang XJ, Sugimura J, Tretiakova MS et al. Gene expression profiling of renal medullary carcinoma: potential clinical relevance. *Cancer* 2004;100(5):976-85.
- <sup>11</sup> Lindgren V, Paner GP, Flanigan RC et al. Renal tumor with overlapping distal nephron morphology and karyotype. *Arch Pathol Lab Med* 2004;128(11):1274-8.
- <sup>12</sup> Kafe H, Verbavatz JM, Cochand-Priollet B et al. Collecting duct carcinoma: an entity to be redefined? *Virchows Arch* 2004;445(6):637-40.
- <sup>13</sup> Assad L, Resetkova E, Oliveira VL et al. Cytologic features of renal medullary carcinoma. *Cancer* 2004 Dec 8; [Epub ahead of print]
- <sup>14</sup> Zerban H, Nogueira E, Riedasch G et al. Renal oncocytoma: origin from the collecting duct *Virchows Arch B Cell Pathol Incl Mol Pathol* 1987;52(5):375-87.
- <sup>15</sup> Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. *Cancer* 2004;101(7):1575-83.
- <sup>16</sup> Broecker B. Non-Wilms' renal tumors in children. *Urol Clin North Am* 2000;27(3):463-9.
- <sup>17</sup> Trappe RU, Riess H, Lippek F et al. Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed Adult Wilms' tumor and a novel alteration in intron 1 of the WT1 gene. *J Pediatr Hematol Oncol* 2004;26(12):820-3.
- <sup>18</sup> Reinhard H, Aliani S, Ruebe C et al. Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study. *J Clin Oncol* 2004 ;22(22):4500-6.
- <sup>19</sup> Peyromaure M, Thiounn N, Scotte F et al. Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. *J Urol* 2003;170(4 Pt 1):1138-40.
- <sup>20</sup> Hayashi Y, Ohi R, Okabe I et al. TNM classification--pediatric tumors. *Gan To Kagaku Ryoho* 1998;25(3):431-41.
- <sup>21</sup> Russo P, Brady MS, Conlon K et al. Adult urological sarcoma. *J Urol* 1992;147(4):1032-6.
- <sup>22</sup> Russo P. Urologic sarcoma in adults. Memorial Sloan-Kettering Cancer Center experience based on a prospective database between 1982 and 1989. *Urol Clin North Am* 1991;18(3):581-8.
- <sup>23</sup> Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. *Medicine (Baltimore)* 1997;76(6):381-91.
- <sup>24</sup> Kondo K, Yao M, Yoshida M et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. *Genes Chromosomes Cancer* 2002;34(1):58-68.
- <sup>25</sup> Semenza GL Regulation of mammalian O<sub>2</sub> homeostasis by hypoxia-inducible factor 1. *Annu Rev Cell Dev Biol* 1999;15:551-78.

- 
- <sup>26</sup> Wenger RH, Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. *Biol Chem* 1997;378(7):609-16.
- <sup>27</sup> Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. *J Biol Chem* 1997;272(36):22642-7.
- <sup>28</sup> Huang LE, Gu J, Schau M et al. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. *Proc Natl Acad Sci U S A* 1998;95(14):7987-92.
- <sup>29</sup> Dang CV, Semenza GL. Oncogenic alterations of metabolism. *Trends Biochem Sci* 1999;24(2):68-72.
- <sup>30</sup> Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. *Curr Opin Genet Dev* 2001;11(3):293-9.
- <sup>31</sup> Buzio L, De Palma G, Mozzoni P. Glutathione S-transferases M1-1 and T1-1 as risk modifiers for renal cell cancer associated with occupational exposure to chemicals. *Occupational and Environmental Medicine* 2003;60:789-793.
- <sup>32</sup> Gnarr JR, Glenn GM, Latif F et al. Molecular genetic studies of sporadic and familial renal cell carcinoma. *Urol Clin North Am* 1993;20(2):207-16.
- <sup>33</sup> Maher ER. Von Hippel-Lindau disease. *Curr Mol Med* 2004;4(8):833-42.
- <sup>34</sup> Bjornsson J, Short MP, Kwiatkowski DJ et al. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. *Am J Pathol* 1996;149(4):1201-8.
- <sup>35</sup> Al-Saleem T, Wessner LL, Scheithauer BW et al. Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex. *Cancer* 1998;83(10):2208-16.
- <sup>36</sup> Mak BC, Yeung RS. The tuberous sclerosis complex genes in tumor development. *Cancer Invest* 2004;22(4):588-603.
- <sup>37</sup> Gregoire JR, Torres VE, Holley KE et al. Renal epithelial hyperplastic and neoplastic proliferation in autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 1987;9(1):27-38.
- <sup>38</sup> Keith DS, Torres VE, King BF et al. Renal cell carcinoma in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 1994;4(9):1661-9.
- <sup>39</sup> Zbar B, Glenn G, Lubensky I et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. *J Urol* 1995;153(3 Pt 2):907-12.
- <sup>40</sup> Zbar B, Tory K, Merino M et al. Hereditary papillary renal cell carcinoma. *J Urol* 1994;151(3):561-6.
- <sup>41</sup> Gago-Dominguez M, Yuan JM, Castela JE et al. Family history and risk of renal cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 2001;10(9):1001-4.
- <sup>42</sup> Mellemegaard A, Engholm G, McLaughlin JK, Olsen JH. Risk factors for renal cell carcinoma in Denmark. I. Role of socioeconomic status, tobacco use, beverages, and family history. *Cancer Causes Control* 1994;5(2):105-13.
- <sup>43</sup> Peces R, Martinez-Ara J, Miguel JL et al. Renal cell carcinoma co-existent with other renal disease: clinico-pathological features in pre-dialysis patients and those receiving dialysis or renal transplantation. *Nephrol Dial Transplant* 2004;19(11):2789-96.
- <sup>44</sup> Heinz-Peer G, Schoder M, Rand T. Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective US study. *Radiology* 1995;195(3):667-71.
- <sup>45</sup> Doublet JD, Peraldi MN, Gattegno B et al. Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. *J Urol* 1997;158(1):42-4.
- <sup>46</sup> Li MK, Choy DK, Yip SK. Renal cell carcinoma in patients with chronic renal failure. *Ann Acad Med Singapore* 1999;28(4):512-5.
- <sup>47</sup> Denton MD, Magee CC, Ovuworie C et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. *Kidney Int* 2002;61(6):2201-9.
- <sup>48</sup> Savaj S, Liakopoulos V, Ghareeb S et al. Renal cell carcinoma in peritoneal dialysis patients. *Int Urol Nephrol* 2003;35(2):263-5.
- <sup>49</sup> Dhote R, Thiounn N, Debre B, Vidal-Trecan G. Risk factors for adult renal cell carcinoma. *Urol Clin North Am* 2004;31(2):237-47.
- <sup>50</sup> McLaughlin JK, Mandel JS, Blot WJ et al. A population--based case--control study of renal cell carcinoma. *J Natl Cancer Inst* 1984;72(2):275-84.
- <sup>51</sup> Wolk A, Gridley G, Niwa S et al. International renal cell cancer study. VII. Role of diet. *Int J Cancer* 1996;65(1):67-73.
- <sup>52</sup> Moyad MA. Obesity, interrelated mechanisms, and exposures and kidney cancer. *Semin Urol Oncol* 2001;19(4):270-9.

- 
- <sup>53</sup> D'Amico A, Piacentini I, Righetti R et al. Exogenous risk factors for parenchymal carcinoma of the kidney. *Arch Ital Urol Androl* 2001;73(1):49-55.
- <sup>54</sup> McLaughlin JK, Chow WH, Mandel JS et al. International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. *Int J Cancer* 1995;63(2):216-21.
- <sup>55</sup> Yuan JM, Castela JE, Gago-Dominguez M et al. Hypertension, obesity and their medications in relation to renal cell carcinoma. *Br J Cancer* 1998;77(9):1508-13.
- <sup>56</sup> Mellemegaard A, Engholm G, McLaughlin JK et al. Risk factors for renal-cell carcinoma in Denmark. III. Role of weight, physical activity and reproductive factors. *Int J Cancer* 1994;56(1):66-71.
- <sup>57</sup> Lindblad P, Mellemegaard A, Schlehofer B et al. International renal-cell cancer study. V. Reproductive factors, gynecologic operations and exogenous hormones. *Int J Cancer* 1995;61(2):192-8.
- <sup>58</sup> Mydlo JH, Chawla S, Dorn S et al. Renal cancer and pregnancy in two different female cohorts. *Can J Urol* 2002;9(5):1634-6.
- <sup>59</sup> Yu MC, Mack TM, Hanisch R et al. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. *J Natl Cancer Inst* 1986;77(2):351-6.
- <sup>60</sup> Kreiger N, Marrett LD, Dodds L et al. Risk factors for renal cell carcinoma: results of a population-based case-control study. *Cancer Causes Control* 1993;4(2):101-10.
- <sup>61</sup> Hiatt RA, Tolani K, Quesenberry CP Jr. Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA). *Cancer Causes Control* 1994;5(4):319-25.
- <sup>62</sup> Muscat JE, Hoffmann D, Wynder EL. The epidemiology of renal cell carcinoma. A second look. *Cancer* 1995;75(10):2552-7.
- <sup>63</sup> Yuan JM, Castela JE, Gago-Dominguez M et al. Tobacco use in relation to renal cell carcinoma. *Cancer Epidemiology, Biomarkers & Prevention* 1998;7(5):429-33.
- <sup>64</sup> La Vecchia C, Negri E, D'Avanzo B, Franceschi S. Smoking and renal cell carcinoma. *Cancer Res* 1990;50(17):5231-3.
- <sup>65</sup> Hunt JD, van der Hel OL, McMillan GP et al. Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies. *Int J Cancer* 2005;114(1):101-8.
- <sup>66</sup> McCredie M, Stewart JH. Risk factors for kidney cancer in New South Wales. IV. Occupation. *Br J Ind Med* 1993;50(4):349-54.
- <sup>67</sup> Brauch H, Weirich G, Hornauer MA et al. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. *J Natl Cancer Inst* 1999;91(10):854-61.
- <sup>68</sup> Pesch B, Haerting J, Ranft U et al. Occupational risk factors for renal cell carcinoma: agent-specific results from a case-control study in Germany. MURC Study Group. Multicenter urothelial and renal cancer study. *Int J Epidemiol* 2000;29(6):1014-24.
- <sup>69</sup> Buzio L, Tondel M, De Palma G et al. Occupational risk factors for renal cell cancer. An Italian case-control study. *Med Lav* 2002;93(4):303-9.
- <sup>70</sup> Bruning T, Pesch B, Wiesenhutter B et al. Renal cell cancer risk and occupational exposure to trichloroethylene: results of a consecutive case-control study in Arnsberg, Germany. *Am J Ind Med* 2003;43(3):274-85.
- <sup>71</sup> Brauch H, Weirich G, Klein B et al. VHL mutations in renal cell cancer: does occupational exposure to trichloroethylene make a difference? *Toxicol Lett* 2004;151(1):301-10.
- <sup>72</sup> Schraml P, Zhaou M, Richter J et al. Analysis of kidney tumors in trichloroethylene exposed workers by comparative genomic hybridization and DNA sequence analysis. *Verh Dtsch Ges Pathol* 1999;83:218-24.
- <sup>73</sup> Kolonel LN. Association of cadmium with renal cancer. *Cancer* 1976;37(4):1782-7.
- <sup>74</sup> McLaughlin JK, Blot WJ, Mehl ES et al. Petroleum-related employment and renal cell cancer. *J Occup Med* 1985;27(9):672-4.
- <sup>75</sup> McCredie M, Stewart JH, Day NE. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. *Int J Cancer* 1993;53(2):245-9.
- <sup>76</sup> McCredie M, Pommer W, McLaughlin JK et al. International renal-cell cancer study. II. Analgesics. *Int J Cancer* 1995;60(3):345-9.
- <sup>77</sup> Gago-Dominguez M, Yuan JM, Castela JE et al. Regular use of analgesics is a risk factor for renal cell carcinoma. *Br J Cancer* 1999;81(3):542-8.
- <sup>78</sup> Lindblad P, Wolk A, Bergstrom R, Adami HO. Diet and risk of renal cell cancer: a population-based case-control study. *Cancer Epidemiol Biomarkers Prev* 1997;6(4):215-23.
- <sup>79</sup> Romanenko A, Morell-Quadreny L, Nepomnyaschy V et al. Radiation sclerosing proliferative atypical nephropathy of peritumoral tissue of renal-cell carcinomas after the Chernobyl accident in Ukraine. *Virchows Arch* 2001;438(2):146-53.

- 
- <sup>80</sup> Blanco Espinosa A, Leva Vallejo M, Merlo de la Pena F et al. Association of renal carcinoma and the exposure to ionizing radiation after the Chernobyl accident. *Actas Urol Esp* 2003;27(2):164-7.
- <sup>81</sup> Darby SC, Kendall GM, Fell TP et al. A summary of mortality and incidence of cancer in men from the United Kingdom who participated in the United Kingdom's atmospheric nuclear weapon tests and experimental programmes. *Br Med J (Clin Res Ed)* 1988;296(6618):332-8.
- <sup>82</sup> Darby SC, Kendall GM, Fell TP. Further follow up of mortality and incidence of cancer in men from the United Kingdom who participated in the United Kingdom's atmospheric nuclear weapon tests and experimental programmes. *BMJ* 1993;307(6918):1530-5.
- <sup>83</sup> Muirhead CR, Kendall GM, Darby SC et al. Epidemiological studies of UK test veterans: II. Mortality and cancer incidence. *J Radiological Protection* 2004;24(3):219-41.
- <sup>84</sup> Vogelzang NJ, Yang X, Goldman S et al. Radiation induced renal cell cancer: a report of 4 cases and review of the literature. *J Urol* 1998;160(6 Pt 1):1987-90.
- <sup>85</sup> Hughes MA, Wang A, DeWeese TL. Two secondary malignancies after radiotherapy for seminoma: case report and review of the literature. *Urology* 2003;62(4):748.
- <sup>86</sup> Schlehofer B, Pommer W, Mellengaard A et al. International renal-cell-cancer study. VI. the role of medical and family history. *Int J Cancer* 1996;66(6):723-6.
- <sup>87</sup> Yang XJ, Sugimura J, Tretiakova MS et al. Gene expression profiling of renal medullary carcinoma: potential clinical relevance. *Cancer* 2004;100(5):976-85.
- <sup>88</sup> Swartz MA, Karth J, Schneider DT et al. Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. *Urology* 2002;60(6):1083-9.
- <sup>89</sup> Kuroda N, Toi M, Hiroi M, Enzan H. Review of collecting duct carcinoma with focus on clinical and pathobiological aspects. *Histol Histopathol* 2002;17(4):1329-34.
- <sup>90</sup> Stjernfeldt M, Berglund K, Lindsten J, Ludvigsson J. Maternal smoking during pregnancy and risk of childhood cancer. *Lancet* 1986;1(8494):1350-2.
- <sup>91</sup> Olshan AF, Breslow NE, Falletta JM et al. Risk factors for Wilms tumor. Report from the National Wilms Tumor Study. *Cancer* 1993;72(3):938-44.
- <sup>92</sup> Schuz J, Kaletsch U, Meinert R et al. High-birth weight and other risk factors for Wilms tumour: results of a population-based case-control study. *Eur J Pediatr* 2001;160(6):333-8.
- <sup>93</sup> Erdogan F, Demirel A, Polat O. Prognostic significance of morphologic parameters in renal cell carcinoma. *Int J Clin Pract* 2004;58(4):333-6.
- <sup>94</sup> Delahunt B. Histopathologic prognostic indicators for renal cell carcinoma. *Semin Diagn Pathol* 1998;15(1):68-76.
- <sup>95</sup> Hermanek P, Schrott KM. Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. *J Urol* 1990;144(2 Pt 1):238-41.
- <sup>96</sup> Ficarra V, Righetti R, Piloni S et al. Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. *Eur Urol* 2002;41(2):190-8.
- <sup>97</sup> Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. *Am J Surg Pathol* 1982;6(7):655-63.
- <sup>98</sup> Goldstein NS. The current state of renal cell carcinoma grading. *Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)*. *Cancer* 1997;80(5):977-80.
- <sup>99</sup> Cheville JC, Lohse CM, Zincke H et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. *Am J Surg Pathol* 2004;28(4):435-41.
- <sup>100</sup> Grabowski M, Huzarski T, Lubinski J, Sikorski A. Survival in patients with rare subtypes of renal cell carcinoma. *BJU Int* 2002;89(6):599-600.
- <sup>101</sup> Mian BM, Bhadkamkar N, Slaton JW et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. *J Urol* 2002;167(1):65-70.
- <sup>102</sup> Cheville JC, Lohse CM, Zincke H et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. *Am J Surg Pathol* 2003;27(5):612-24.
- <sup>103</sup> Kim HL, Belldegrin AS, Freitas DG et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. *J Urol* 2003;170(5):1742-6.
- <sup>104</sup> Fahn HJ, Lee YH, Chen MT et al. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. *J Urol* 1991;145(2):248-50.
- <sup>105</sup> Gomez Jimenez J, Martinez Torres JL, Carvia Ponsaille R et al. Leiomyosarcoma and rhabdomyosarcoma: rare tumors of the kidney. *Actas Urol Esp* 1998;22(5):434-7.
- <sup>106</sup> Spellman JE Jr, Driscoll DL, Huben RP. Primary renal sarcoma. *Am Surg* 1995;61(5):456-9.
- <sup>107</sup> Srinivas V, Sogani PC, Hajdu SI, Whitmore WF Jr. Sarcomas of the kidney. *J Urol* 1984;132(1):13-6.

---

<sup>108</sup> Strouse JJ, Spevak M, Mack AK et al. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. *Pediatr Blood Cancer* 2004;44(4):407-411.

<sup>109</sup> Kalapurakal JA, Nan B, Norkool P et al. Treatment outcomes in adults with favorable histologic type Wilms tumor-an update from the National Wilms Tumor Study Group. *Int J Radiat Oncol Biol Phys* 2004;60(5):1379-84.

<sup>110</sup> Terenziani M, Spreafico F, Collini P et al. Adult Wilms' tumor: A monoinstitutional experience and a review of the literature. *Cancer* 2004;101(2):289-93.